A Phase 2/3 interventional study of Methadone (100% dose) and Methadone (50% dose) in Opioid Use Disorder, Chronic Pain and Methadone, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by University of Maryland, Baltimore · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing methadone in Opioid-Related Disorders — 4 open to participants now, 4 under way, 1 of them phase 3. Methadone · Opioid-Related Disorders.
Among the 19 studies testing methadone in Opioid-Related Disorders, this one is the 8th largest by planned enrollment, is one of 2 that started in 2023, is one of 2 in phase 2/3, and was the 16th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →4 of the 19 studies testing methadone in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:
Ashish P Thakrar, MD MS · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–99
Pouya Azar · Sites in Canada
Ages 19+
By country, each count listing its studies:
Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 5 · Phase 4 5
First in 1995; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 68 across the 19 interventional studies. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 19 have an industry lead sponsor. The 10 most frequent:
University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 131 are open to participants now.
Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.
16 studies in Opioid-Related Disorders by University of Maryland, Baltimore: 6 open now, 8 under way, 2 of them phase 3. Of 7 finished, 1 (14%) have results posted.
Among the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 2/3, and was the 7th registered.
University of Maryland, Baltimore’s Opioid-Related Disorders studies by the year they started, since 2017.
2 of the studies testing methadone in Opioid-Related Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT07546396Pouya AzarMethadone Rapid Restart | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies testing methadone in Opioid-Related Disorders, from their registry updates:
Among University of Maryland, Baltimore’s 16 in Opioid-Related Disorders:
This tab as a report to print or save as PDF → With an account.
This study will evaluate whether once versus twice daily dosing of methadone will be an effective method for managing comorbid pain and opioid use disorder.
This study follows a successfully completed project (NCT03254043) to now pursue the investigators overarching goal of optimizing methadone dosing as a method for managing comorbid chronic pain and opioid use disorder (OUD) among persons receiving methadone for the treatment of OUD. Up to 62% of persons maintained on methadone for OUD experience clinically significant pain, versus 31% in the general population. Pain in methadone-maintained persons (MMP) is associated with poor OUD treatment outcomes and severe distress. No effective treatment for comorbid pain and OUD currently exists; though preclinical and human data suggest divided methadone dosing may be a more optimal strategy for managing pain than once daily dosing, this has never been empirically examined. This study will evaluate an intervention for comorbid chronic pain among MMP using a Phase II double-blind, randomized, placebo-controlled comparison of treatment as usual (TAU) versus split daily methadone dosing for 12-weeks. Methadone will be remotely managed via an electronic pillbox. Outcomes will include weekly assessments of pain and OUD outcomes, ecological momentary assessment of pain before and after dosing, and point-prevalence measures of laboratory-induced pain to explore mechanism of effects. If effective, this approach could transform the care of MMP with pain because it would be feasible to implement within the operational structure of a methadone clinic and would impose low provider burden. Results could provide a high magnitude treatment for the substantial number of MMP who experience daily pain with no reliable form of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in treatment as usual group will receive 100% active methadone in AM + placebo in PM.
Drug: Methadone (100% dose)
Participants in split dosing group will receive 50% active methadone + placebo twice daily.
Drug: Methadone (50% dose)
Methadone for the treatment of opioid use disorder
Methadone for the treatment of opioid use disorder
Change in worst pain rating- past 24 hour as assessed by the Brief Pain Inventory scale
Using the Brief Pain Inventory rating of "Worst Pain" in the past 24 hours, rated on a scale of 1-10, collected once weekly during weeks 1 through 12 of the intervention.
Time frame: Week 1 up to week 12
Change in Pain Tolerance Latency
Time in seconds (0-300) to removal of hand from cold pressor measure of laboratory-induced pain, collected point-prevalence during weeks 1, 6, and 12 of the intervention.
Time frame: Weeks 1, 6, and 12
Change in Pain Interference- past 7 days as assessed by Pain-related Disability Scale Total Score
Past 7 day Pain-related Disability Scale Total Score (range 0-70), collected once weekly during weeks 1 through 12 of the intervention.
Time frame: Week 1 up to 12
Change in Opioid Withdrawal Severity- past 24 hours as assessed by the Subjective Opioid Withdrawal Scale
Past 24 hour total score (range 0-64) for the Subjective Opioid Withdrawal Scale (SOWS), collected once weekly during weeks 1 through 12 of the intervention.
Time frame: Week 1 up to 12
Plan to share: No
Started Feb 2023 (actual). Primary completion is estimated for Jun 2027, 51 months after the start.
Of 18 phase 2/3 interventional studies under Opioid-Related Disorders, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 85. This study's planned 51 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methadone
University of Maryland, Baltimore →